Conflict of interest: Andreas Schneeweiss served as a consultant for Sanofi Aventis and Eli Lilly and has received research funding from Sanofi Aventis and Eli Lilly. None of the other authors have any potential conflict of interest to declare.
Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials
Article first published online: 16 MAR 2013
Copyright © 2013 UICC
International Journal of Cancer
Volume 133, Issue 4, pages 1006–1015, 15 August 2013
How to Cite
Marmé, F., Aigner, J., Lorenzo Bermejo, J., Sinn, P., Sohn, C., Jäger, D. and Schneeweiss, A. (2013), Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials. Int. J. Cancer, 133: 1006–1015. doi: 10.1002/ijc.28094
- Issue published online: 11 JUN 2013
- Article first published online: 16 MAR 2013
- Accepted manuscript online: 7 FEB 2013 07:05AM EST
- Manuscript Accepted: 3 JAN 2013
- Manuscript Received: 2 OCT 2012
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions and you will be able to log in to access content. Some users may also log in directly via OpenAthens.
Please note that there are currently a number of duplicate entries in the list of institutions. We are actively working on fixing this issue and apologize for any inconvenience caused.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.